Swedish Oasmia Pharmaceutical said on Tuesday that it got a patent for its unique nanotech method to produce novel pharmaceutical formulations, from the United States Patent and Trademark Office (USPTO).
The patent covers the method to characterize Oasmia´s patented excipient XR17, that delivers human and animal cancer drugs less invasive and more effectively. Thus, the patented method is an advantageous substitute technology that contributes to the development of competing drugs such as well-established cancer treatments.
This novel character is due to lack of prior inventions with the same features. This status has resulted in a very quick patent filling process of less than two years. In comparison, the 2017 new drug approvals median time in USA is of 14 years. The patent will be valid through 2036.
It is also important to note that, although the granted patent is for a method of production, the products produced by the method are also protected by the patent claims in accordance with Article 64(2) of the European Patent Convention. The functional claims of the patent have been partially or fully tested by FDA (Food and Drug Administration) and EMA (European Medical Agency).
The notification confirms the inventive nature of the method, outlined in the patent application, both as a less complex and a simpler method of production, as well as providing and increasing yield at comparable reaction times when compared to competing methods.
This event opens further the possibility to develop new potential licensing revenues, to address alternative markets and achieve further synergies in production, marketing and sales.